Tag: atopic dermatitis
May 9, 2018
AnaptysBio Announces First Quarter 2018 Financial Results and Provides Pipeline Updates
AnaptysBio (Nasdaq:ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on unmet medical needs in inflammation, reported operating...
April 9, 2018
Menlo Therapeutics’ Phase 2 Trial Results in Massive Share Price Fall
Menlo Therapeutics announced that its drug candidate serlopitant showed no significant difference over the placebo to reduce atopic dermatitis. April 9, 2018
Menlo Therapeutics Announces Results from a Phase 2 Trial of Serlopitant for Pruritus Associated with Atopic Dermatitis
Menlo Therapeutics (NASDAQ:MNLO), a late-stage biopharmaceutical company focused on the development of serlopitant for the treatment of pruritus associated with... March 29, 2018
Menlo Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results
Menlo Therapeutics (NASDAQ:MNLO), a late-stage biopharmaceutical company focused on the development of serlopitant, for the treatment of pruritus associated with... March 27, 2018
AnaptysBio Announces Positive Top-Line Proof-of-Concept Data For ANB020 In Moderate-to-Severe Baseline
AnaptysBio (Nasdaq:ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on unmet medical needs in inflammation, today announced... March 15, 2018
Sienna Biopharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results
Sienna Biopharmaceuticals (NASDAQ:SNNA) reported the Company’s financial results for the fourth quarter and full year of 2017. As quoted in the... March 6, 2018
